- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 21
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 21, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 21.
Number 5: Stakeholder groups, including the American College of Rheumatology and the Biotechnology Innovation Organization are praising the enactment of the FDA Reauthorization Act of 2017, calling the law critical to bringing biosimilar products to the marketplace.
Number 4: Drug maker Alexion has announced 3 new US patents that will defend its Soliris against biosimilar competition. Alexion also announced that the European Commission has granted the drug an extended indication for myasthenia gravis.
Number 3: A recently published study shows that biosimilar filgrastim is safe, effective, and well tolerated in both primary and secondary prevention of chemotherapy-induced febrile neutropenia.
Number 2: The FDA has signed an agreement to share confidential information, including trade secrets and inspection reports, with European regulators.
And Number 1: The Center for Biosimilars® Peer Exchange®, titled “Clinical Advances and Challenges with Biosimilars,” kicks off with an expert discussion of the adoption of biosimilar treatments in the United States and Europe.
Finally, last week, our newsletter asked you to share your thoughts about how the FDA should address the deficiencies it observed at Biocon’s manufacturing facility. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
